Pfizer (PFE) EV to FCF (2009 - 2026)

Pfizer (PFE) has reported EV to FCF for 18 consecutive years, with 420.69 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to FCF rose 505.15% year-over-year to 420.69 in Q2 2026; TTM through Jun 2026 was 11.57, a 79.73% decrease from a year earlier, with the FY2025 full-year figure at 14.14, up 6.81% from the prior year.
• EV to FCF was 420.69 for Q2 2026 at Pfizer, up from 64.87 in the prior quarter.
• Over five years, EV to FCF peaked at 2885.24 in Q2 2023 and troughed at 103.83 in Q2 2025.
• A 5-year average of 270.65 and a median of 37.14 in 2023 frame the typical range for EV to FCF.
• The widest YoY moves for EV to FCF: up 6304.22% in 2023, down 318.35% in 2023.
• Over 5 years, EV to FCF stood at 35.09 in 2022, then rose by 1.98% to 35.79 in 2023, then grew by 7.57% to 38.49 in 2024, then decreased by 25.99% to 28.49 in 2025, then soared by 1376.61% to 420.69 in 2026.
• The last three EV to FCF figures came in at 420.69 (Q2 2026), 64.87 (Q1 2026), and 28.49 (Q4 2025), per Business Quant data.